Data from two Phase II clinical trials conducted by Aeras and partners indicate promise for future of TB vaccine development.

Publication of primary results in the New England Journal of Medicine shows positive impact of innovative vaccine technology in clinical trial conducted in tuberculosis endemic regions.

Trial offers hope for new revaccination strategies with Bacille Calmette-Guerin (BCG) against TB, the world’s leading infectious disease killer.

Results from innovative Phase 2 tuberculosis vaccine trial offer potential for new BCG revaccination strategies, hope for subunit vaccines

Aeras releases a document providing systematic guidance on how to effectively engage stakeholders throughout the entire life cycle of TB vaccine research.

Rockville, MD, September 28, 2016 –Aeras, a nonprofit research and development organization dedicated to the development of new TB vaccines, has launched the AerasSHARE Biorepository, a new website to allow researchers from other organizations to access specimens and datasets that were collected by Aeras and its research partners in an effort to facilitate state-of-the-art TB vaccine related science and promote world-wide collaboration among TB vaccine researchers.

The Sanofi Pasteur-Aeras Joint Steering Committee for the Phase 2 trial (C-040-404/TUB09) convened on 14 June 2016 to review and discuss the recommendations of the study’s independent Data Monitoring Committee (DMC).

Rockville, MD., USA and Dessau, Germany, June 23, 2015 – Aeras and IDT Biologika today announced a strategic partnership that includes the acquisition of Aeras’s Biopharmaceutical Development Center (BDC) manufacturing facility by IDT.

The TB Unmasked infographic tells a data-driven story about the risk faced by those on the front lines of tuberculosis. Nurses, doctors and healthcare professionals of all types are getting TB far too often and we must do more. It starts with education.

TB Unmasked: from the front lines of the TB epidemic, a new documentary by Aeras about healthcare workers and the reasons why this critical workforce deserves to be protected.